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Recent Advances in Endocrinology
In this issue of the Journal we publish some of the papers presented at an
Interdisciplinary Meeting on Recent Advances in Endocrinology, which was held on 17
March 1973, at Groote Schuur Hospital, Cape Town, under the Chairmanship of
Professor J. H. Louw.
The four guest editorials in this issue, by Professor Jackson, and Drs Vinik, Pimstone
and Epstein, were specially written to relate to the articles and should be read in con-
junction with these.
In order to ensure that the articles would indeed incorporate the most recent ad-
vances in the field of endocrinology, and because of the lapse of time between the
presentation of the original papers and publication, all the material included in this
issue was submitted to the various authors for revision and addition during November
1973.
Ectopic Production of Hormones by
Non-endocrine Tumours
Modem techniques of hormone assay-especially
radio-immunoassay-have led to a clearer under-
standing of many bizarre syndromes connected with
cancers. Cancer cells have been shown to be able
to synthesise polypeptides identical with or closely
resembling almost all known peptide hormones, and
can thus mimic the known 'too-much' endocrine
syndromes and even produce a few new ones. Hor-
mones produced by tumours of non-endocrine
organs are known as 'ectopic'. Obviously, not all
tumoral hormone production is ectopic, for example
insulin from an insulinoma, calcitonin from a
thyroid medullary cell carcinoma, gastrin from the
delta cells of the pancreatic islets in the Zollinger-
Ellison syndrome. The TSH production by tropho-
blastic neoplasms is also, strictly speaking, not
ectopic, as admitted by Jackson in his review in
this issue (see page 347).
Immunoassay has led to the discovery that such
ectopic hormone production is common, but fre-
quently unaccompanied by any evident clinical
manifestations. Thus an alpha cell tumour of the
pancreatic islets produced not only glucagon, its
proper hormone, but also gastrin, corticotrophin,
and melanocyte-stimulating, antidiuretic, and para-
thyroid hormones. On the other hand, hypoglycae-
mia, associated particularly with large mesenchymal
tumours and hepatoma, has never clearly been
shown to be caused by overproduction of insulin.
Two cases of interest have recently been reported
from Groote Schuur Hospital. The first was that of
a' 30-year-old man presenting with Cushing's syn-
drome, for which he underwent bilateral total
adrenalectomy.' One year later a thymoma was dis-
covered, which had rapidly enlarged. The removed
tumour contained large amounts of ACTH (by
radio-immunoassay) and secretory granules were
demonstrated by electron microscopy. The second
case was a 50-year-old man who presented with the
syndrome of excessive secretion of antidiuretic hor-
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mone (ADH) together with clinical and biochemical
hypopituitarism.' At autopsy a bronchogenic oat-
cell carcinoma was found with metastases to the
hypothalamus and pituitary gland. Neurosecretory
granules were seen in the tumour on electron micro-
scopy, and immunoassay demonstrated that it con-
tained large amounts of ADH, which was apparent-
ly identical with the naturally-occurring arginine
vasopressin.
Many tumours are specific with regard to their
ectopic endocrine activities. Thus the ectopic hyper-
parathyroid syndrome occurs with squamous cell
bronchial carcinoma, whereas most other endocrine
disorders associated with bronchial neoplasms occur
with the less common oat-cell tumour. Hepatoma is
particularly related to precocious puberty in boys
(gonadotrophins), erythrocytosis (erythropoietin)
and hypoglycaemia (unknown mechanisms). Certain
diagnostic implications may arise. For instance the
discovery of hypokalaemic alkalosis or of dilutional
hyponatraemia should suggest the presence of an
oat-cell bronchial neoplasm even without any con-
firmatory radiological evidence. Gynaecomastia
with a pulmonary lesion suggests an LH-producing
tumour. A neat negative inference sometimes occurs
in cases of breast carcinoma. In this condition any
hypercalcaemia is not due to ectopic parathyroid
hormone but to actual skeletal replacement, and
consequently the serum phosphate is also raised.
Hence in cases with low serum phosphate, true
primary hyperparathyroidism is usually present as
a coincidental disease.
Clubbing of the fingers and toes and the more
striking hypertrophic osteo-arthropathy are asso-
ciated with lung tumours and may regress rapidly
if the primary growth can be removed. Ectopic
growth hormone production by the tumour has been
postulated as the cause, but this cannot be con-
sidered proved. Many other unexplained pheno-
mena can accompany cancer. These includemyo-
pathies, neuropathies, encephalopathy, myelopathy;
acanthosis nigricans, ichthyosis, dermatomyositis,
dermatitis herpetiformis, vascular thromboses,
leukaemoid and leuco-erythroblastic reactions, red
cell aplasia, eosinophilia; proteinopathies and
amyloidosis and nephrotic syndrome. It is quite
likely that as yet unrecognised polypeptides, or
perhaps other chemical agents, produced by the pri-
mary tumour, will be found to be responsible for
many of these complications of cancer. It is also
possible that cancers produce further chemical sub-
stances, which may be polypeptides, that impair the
functions of normal body tissues and lead to the
anaemia and cachexia of the victim, and even to his
death, the precise mechanism of which is not re-
vealed by an autopsy at which the vital organs
appear substantially undamaged.
W. P. U. JACKSON
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The Entero-Insular Axis
As early as 1902 Moore and colleagues] demon-
strated a blood sugar-lowering effect of acid alcohol
extracts of dog duodenum. Fifty years later it was
shown that glucose disappeared more rapidly from
blood when given orally than when a comparable
dose was given intravenously. This phenomenon
was shown to be insulin-mediated, and a gut in-
sulinotrophic honnone 'incretin' postulated.
Several gut hormones are contenders for this
title, since all have been shown to release insulin
in vitro. These include gastrin, secretin, cholecysto-
kinin-pancreozymin (CCK-PZ) gut glucagon, and
two recently discovered hormones, gastro-intestinal
inhibitory peptide (GIP) and vasa-active intestinal
polypeptide (VIP). Controversy still exists as to
which, if any, of these hormones fulfil the role of
'incretin',' but undoubtedly a hormone, or group of
hormones, produced in the gut, are insulinotrophic.
Glucose stimulates insulin release from several
postulated functional pools in the pancreas, and it
seems that gut hormones can stimulate insulin
secretion from the acute release pool, as well as
from a defined glucose-independent source. Thus
in diabetics whose pancreases are unresponsive to
glucose, gut hormones may nevertheless stimulate
insulin secretion.
The hypothetical role of these gut insulinotrophes
would then be to minimise fluctuations in blood
-
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glucose following a meal by anticipating the arrival
of metabolic substrates in the blood, and evening
out large swings in blood glucose levels. Further,
since CCK-PZ, primarily released after mixed fat
and protein meals, also stimulates glucagon release,
it appears suited to re-direct body metabolism to-
wards protein storage by increasing insulin secre-
tion and providing alternative energy substrate in
the form of glucose derived from glucagon-stimu-
lated glycogenolysis.
Maturity onset diabetics in whom insulin resis-
tance, rather than insulin deficiency, results in
glucose intolerance, demonstrate excessive early
insulin responses to oral glucose. Thus, overactivity
of the entero-insular axis due to primary hyper-
secretion of gut hormones may be the earliest
lesion in diabetics, and the fault lies in the gut and
not in the pancreas at all!
That an exaggerated fall in blood glucose follow-
ing a meal, referred to as reactive hypoglycaemia,
is not due to insulin oversecretion is noW fairly
well accepted. It appears instead that there is over-
secretion in sensitive individuals of gut glucagon
which is devoid of glycogenolytic activity, but com-
petes with pancreatic glucagon for receptors in the
liver, thus antagonising the glycogenolytic action
of the latter and permitting unopposed insulin
action, causing an excessive fall in blood glucose
concentration.
Lastly, an oral phase of insulin secretion has
been shown in dogs which may be neurally or
neurohormonally mediated. Hence, it may not only
be excessive food intake which after digestion leads
to obesity, hyperinsulinism and diabetes, but also
that which is contemplated or enters the mouth.
The postulated sequence would thus be oversecre-
tion of insul in, increasing fat stores resulting in
obesity, insulin resistance and diabetes.
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FSH/LH-RF
It is almost forty years since Popa and Fielding'
demonstrated a portal venous system connecting
the median eminence in the hypothalamus with the
anterior pituitary gland. Green and Harris' sub-
sequently postulated the hypothalamic control of
anterior pituitary function, probably by a neuro-
humeral mechanism. Later experimentation'" using
electrical stimulation or destruction of the hypo-
thalamus or its pathways, demonstrated the hypo-
thalamic control of pituitary follicle-stimulating
hormone (FSH) and luteinising hormone (LH). This
concept has been confirmed by the extraction from
pig5 and sheep' hypothalami of a highly purified pep-
tide able to release both FSH and LH. It has since
been identified as a decapeptide' which has recently
been synthesised: The availability of synthetic FSH/
LH-releasing factor (FSH/LH-RF) during the past
two years has led to a flurry of physiological studies
on the control of gonadotrophin secretion. It appears
that a single peptide controls both FSH and LH
release9 under normal circumstances, a larger
amount of LH being discharged at a given dose of
the releasing factoL'O The presence of oestrogen
appears to favour an effect on LH,H whereas in the
prepubertal child there is greater tendency for FSH
to respond.'o,,, Gonadotrophin release may be 'pro-
voked before puberty,W,,,,13 even in infancy." In rats,
responsiveness of both FSH and LH to FSH/LH-RF
increases until puberty, after which some decline
occurs," but a full study on age and gonadotrophin
release in man has not yet appeared. There is a
slightly greater gonadotrophin response to the re-
leasing factor in the luteal phase of the menstrual
cycle and a marked increase just before ovulation."
FSH/LH-RF does not appear to release any other
pituitary hormone except occasionally growth hor-
mone in acromegalies." Clinically, it is being ex-
tensively used as a test of pituitary gonadotrophin
reserve. In particular, it has been useful in dis-
tinguishing between delayed puberty (in which
normal responses are obtained) and organic disease
of the hypothalamus and pituitary in which responses
are either flat or grossly attenuated.'o In spite of the
direct provocative effect on the anterior pituitary
gland, patients with hypogonadism due to hypo-
thalamic disease usually (but not always) fail to
show normal response to FSH/LH-RF,'o probably
because the resting pituitary needs prior activation
by endogenous releasing factor before responding
to the exogenous administration of the peptide. In
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this respect It IS unlike hypothalamic hypothyroid-
ism in which good TSH responses to thyrotrophin-
releasing factor have been demonstrated."
There is much interest in the therapeutic potential
of FSH/LH-RF. It has been shown to induce ovu-
lation in patients with secondary amenorrhoea pre-
viously unresponsive to clomiphene, in whom normal
LH responses to FSH/LH-RF had been obtained:'"
Subsequent pregnancy has ensued without super-
ovulation, suggesting that the more physiological
levels of LH induced by this technique are less
hazardous than those obtained by clomiphene or
other hormonal regimens. Of greater import are the
attempts to synthesise biologically inactive ana-
logues of FSH/LH-RF which compete with the
naturally occurring peptide for binding to the
anterior pituitary, and so effectively act as contra-
ceptive agents: As the administration of the peptide
appears to be singularly free of side-efIects,lO this
approach to the problem of contraception is being
assiduously explored in many centres.
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What's New •In Osteoporosis?
Generalised osteoporosis is defined as a disorder of
bone characterised by a progressive loss of bone
mass until the skeleton is inadequate for mechani-
cal support. The chemical composition of the re-
maining bone is virtually normal. The aetiology
and the basic defects causing this common disease
in elderly men and postmenopausal women remain
speculative, but popular theories that have evolved
have been the hormonal one, and disturbances of
calcium metabolism. The hormonal theory was
favoured by Albright because of the fact that an
induced menopause was associated with the early
development of osteoporosis, the presence of mild
osteoporosis in hypogonadal states, and the benefi-
cial effects of sex hormone therapy, especially oestro-
gens, on pain and calcium balance. Nordin, on the
other hand, felt that a deficiency of calcium pro-
voked osteoporosis. This deficiency could be caused
by a combination of factors such as a low calcium
intake, poor absorption and a high urinary loss.
Another cause aggravating or precipitating such a
disease state may well be vitamin D deficiency,
with osteomalacia and not osteoporosis .producing
bone rarefaction, especially in the elderly. Sub-
clinical hyperparathyroidism, perhaps resulting from
an imbalance between the two calcium-regulating
hormones, viz. parathyroid hormone and thyro-
calcitonin, with the former being the predominant
hormone, has also been postulated as a mechanism.
Each of these theories can be made to seem
plausible but they are not really mutually exclusive;
some truth may well be in all of them.
There are a number of other unanswered ques-
tions; what is the exact role of aging? Why are
only a certain number of people afflicted with the
disease osteoporosis, despite the generally agreed
fact that bone density decreases with age? Do these
people have a reduced bone mass initially? Why
are the elderly people of certain races practically
exempt from the disease, e.g. Blacks? Why is
it so difficult to replace bone mass and restore bone
density despite large loads of calcium, and any
other therapy one cares to mention, even when
positive balance is achieved? What is the mecha-
nismof bone pain? Why is the skull so rarely in-
volved in generalised osteoporosis? Despite these
-
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unsolved mysteries, some minor advances have
been made in the therapy of this debilitating
disease.
The beneficial effects of the hormone thyrocal-
citonin, when used as therapy for conditions charac-
terised by high rate of bone turnover, such as
Paget's disease, and hypercalcaemia of diverse
origins, have been demonstrated. Thyrocalcitonin
inhibits bone resorption and thus has a tendency
to produce hypocalcaemia and hypophosphataemia.
It was appealing to explore the po~sibility of using
synthetic thyrocalcitonin as therapy for osteo-
porosis where bone resorption exceeds bone forma-
tion. The optimism was dampened by a lack of re-
sponse both in calcium balance and relief of bone
pain to the administration of porcine and salmon
thyrocalcitonin. The use of human thyrocalcitonin
together with calcium and phosphate supplementa-
tion may offer advantages over the previous therapy
and prove of benefit in the disease. One of the
major disabilities endured by osteoporotic patients
is severe back pain. Calcium infusions of 15 mg/kg
body mass given intravenously in 1 litre of 5%
dextrose water every 4 hours for 12 consecutive
days, has been used successfully by Pak et al.'
in the treatment of this symptom. Results at Groote
Schuur Hospital have also been most encouraging,
not only in the postmenopausal and idiopathic
osteoporotic patient, but also in osteoporosis from
iatrogenically induced hypercortisolism. The
rationale for this therapy is that the hypercalcaemia
produced will switch off non-autonomous sub-
clinical hyperparathyroidism which may be pro-
ducing the osteoporosis. One of the drawbacks of
the therapy is the need for repeated courses.
The predominant effect of fluoride therapy on
bone is osteoblastic stimulation. The mechanism of
this effect is unknown, but it may be that fluoro-
hydroxyapatite facilitates the passage of electric
impulses, which stimulates osteoblasts. This re-
action suggested that fluoride may be useful in the
treatment of osteoporosis. However, the newly-
formed bone was found to be poorly calcified, and
osteomalacia and secondary hyperparathyroidism
frequently coexisted. This therapy fell out of vogue
until revived by Jowsey et al.,' who proposed the
addition of vitamin D and calcium together with
a smaller dose of fluoride to try to improve osteo-
porotic bone. The results to date with this therapy
appear promising.
Lastly, what is the place of oestrogens in these
new therapeutic schedules? They have a role in the
treatment of postmenopausal osteoporosis in pre-
venting bone demineralisation. It has also recently
been shown that oestrogens tend to increase bone
mineral content in postmenopausal females, pro-
vided they are given within 3 years after the onset of
the menopause: Perhaps they may be used with
greater effect in combination with fluoride or cal-
citonin, or with added calcium and supplemented
vitamin D. Clearly their therapeutic role has still to
be defined, whereby they can be employed to their
optimal advantage.
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